Bessemer Group’s Celldex Therapeutics CLDX Stock Holding History

Bessemer Group’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-60	Closed	-$2K	–	2488
2024 Q3	$2K	Buy	+60	New	+$2.29K	﹤0.01%	2176

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bessemer Group's CLDX Position: Q4 2024 in Review

Bessemer Group sold out of Celldex Therapeutics (CLDX) in Q4 2024, closing a stake of 60 shares — an estimated $2K sold.

Bessemer Group first reported a position in CLDX in Q3 2024 and held it in 1 quarter. The position peaked at $2K in Q3 2024. 174 funds tracked by Wall St. Rank hold CLDX as of Q4 2024.

Bessemer Group reported no remaining Celldex Therapeutics position as of Q4 2024 after selling out during the quarter.
Bessemer Group sold 60 Celldex Therapeutics shares in Q4 2024, an estimated $2K.
Bessemer Group first reported a position in Celldex Therapeutics in Q3 2024 and held it in 1 quarter.
Bessemer Group's Celldex Therapeutics position peaked at $2K in Q3 2024.
174 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2024.

Based on Bessemer Group's 13F filing for Q4 2024, filed 13 Feb 2025.